title: Bevacizumab prior to vitrectomy for diabetic traction retinal detachment.
abstract: OBJECTIVE
  To assess the efficacy and safety of preoperative intravitreal bevacizumab (IVB) before vitrectomy for diabetic tractional retinal detachment (TRD).
  
  
  METHODS
  Using ICD-9 codes, we located all patients with diabetic TRD who underwent 3-port 20-gauge vitrectomy primarily performed by one surgeon between January 2004 and January 2009. Eyes receiving IVB were compared with those not. The following outcomes were compared: visual acuity (VA), duration of surgery, and complication rates.
  
  
  RESULTS
  A total of 99 eyes of 90 patients were included in the analysis. In all, 34 patients received IVB on an average of 11.5 (range, 3-30) days previtrectomy. Age was 46.5 and 51.6 in the IVB and non-IVB groups, respectively. VA was improved significantly in both groups: from 20/617 to 20/62 in the IVB group, and from 20/443 to 20/86 in the non-IVB group (P=0.11 between groups). Operating time and postoperative complications (glaucoma, RD, and revitrectomy rate) were similar in both groups. On comparing IVB and non-IVB eyes in younger patients (≤ 40), operating time was shorter (P=0.02) and a trend to better VA in the IVB group was seen.
  
  
  CONCLUSIONS
  Preoperative IVB may be a useful adjunct to vitrectomy for severe PDR complicated by TRD, particularly in younger diabetics.
authors: Department of Ophthalmology and Eye Care Services, Henry Ford Hospital, Detroit, MI 48202, USA. pokroyr@yahoo.com
authors: R
authors: R
authors: Pokroy
authors: U R
authors: UR
authors: Desai
authors: E
authors: E
authors: Du
authors: Y
authors: Y
authors: Li
authors: P
authors: P
authors: Edwards
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D058449:Intravitreal Injections; D007902:Length of Stay; D008875:Middle Aged; D011300:Preoperative Care / Q000379:methods; D012163:Retinal Detachment / Q000503:physiopathology / Q000601:surgery*; D015861:Retinal Neovascularization / Q000503:physiopathology / Q000517:prevention & control; D012189:Retrospective Studies; D015983:Selection Bias; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab